ARTICLE | Product Development
COVID-19 roundup: Emergency use of Moderna vaccine could come earlier than expected; plus ASCO goes virtual, Galapagos pauses filgotinib trials and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 25, 2020 1:41 AM UTC
The overarching news was negative for biopharma Tuesday, with a fresh round of companies announcing trial delays. But Moderna offered a rare ray of light, hinting that its vaccine could be available sooner than many expected. On top of that, ASCO joined the list of conferences turning to a digital format.
Moderna Inc. (NASDAQ:MRNA) revealed in an SEC filing that CEO Stéphane Bancel had indicated on March 20 to Goldman Sachs that mRNA-1273 might be available as soon as this fall under emergency use to individuals including healthcare professionals. He has said the vaccine could be commercially available in 12-18 months...